Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALNY
  • CUSIP: 02043Q10
  • Web: www.alnylam.com
Capitalization:
  • Market Cap: $6.87 billion
  • Outstanding Shares: 86,190,000
Average Prices:
  • 50 Day Moving Avg: $79.44
  • 200 Day Moving Avg: $58.71
  • 52 Week Range: $31.38 - $86.92
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.13
  • P/E Growth: -0.34
Sales & Book Value:
  • Annual Revenue: $58.77 million
  • Price / Sales: 116.89
  • Book Value: $9.65 per share
  • Price / Book: 8.26
Profitability:
  • EBIDTA: ($407,540,000.00)
  • Net Margins: -705.11%
  • Return on Equity: -42.90%
  • Return on Assets: -32.56%
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 6.23%
  • Quick Ratio: 6.23%
Misc:
  • Average Volume: 1.09 million shs.
  • Beta: 2.98
  • Short Ratio: 8.67
 
Frequently Asked Questions for Alnylam Pharmaceuticals (NASDAQ:ALNY)

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings results on Friday, May, 5th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.22) by $0.03. The firm earned $19 million during the quarter, compared to analysts' expectations of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. Alnylam Pharmaceuticals's revenue for the quarter was up 160.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.21) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When will Alnylam Pharmaceuticals make its next earnings announcement?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Alnylam Pharmaceuticals.

Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?

18 brokerages have issued twelve-month target prices for Alnylam Pharmaceuticals' shares. Their predictions range from $36.00 to $131.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $81.17 in the next year. View Analyst Ratings for Alnylam Pharmaceuticals.

What are analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)
  • 2. Needham & Company LLC analysts commented, "Alnylam reported additional results from Phase 2 OLE trial of fitusiran in Hemophilia A and B pts w/ and w/ o inhibitors. Efficacy w/ respect to Annualized Bleeding Rate and target antithrombin knockdown remains favorable and consistent w/ prior data from this program. Alnylam reported several asymptomatic >3X ALT elevations, one of which led to a discontinuation. Mgmt believes these events may be tied to HCV infection, highlighting that all events occurred in pts w/ history of HCV and most significant events were observed in pts w/ active infection. Alnylam is excluding Hemophilia pts w/ active HCV infection from Phase 3 trials. Data from Phase 1 trial published today are not consistent with a dose-dependent impact on ALT elevation. We continue to have a favorable view towards the program given current overall profile (safety, efficacy, and convenience), but acknowledge a level of risk around liver enzymes, which will probably not be clarified until Phase 3 completed." (7/10/2017)
  • 3. Chardan Capital analysts commented, "We now seen Alnylam as the leader in the clinical HBV RNAi therapy space. As discussed in our 14 October 2016 company note for Arbutus (Buy), we believe ARB-1467 has demonstrated at best mediocre phase IIa results that were predictable based on inferior preclinical data relative to Alnylam’s RNAi asset, ALN-HBV . Additionally, ALN-HBV has a favorable dosing route in subcutaneous delivery compared to Arbutus’ ARB-1467 and ARB-1740, which are administered by intravenous injection. With Arrowhead moving to preclinical development in HBV , we now view Alnylam as the leader in the space." (11/30/2016)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:

  • Michael W. Bonney, Independent Chairman of the Board
  • Barry E. Greene, President
  • John M. Maraganore Ph.D., Chief Executive Officer, Director
  • Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer
  • Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President
  • Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development
  • Laurie B. Keating, Senior Vice President, General Counsel, Secretary
  • Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
  • Theresa Heggie, Senior Vice President, Head of Europe and Canada
  • Peter F. Smith Ph.D., Senior Vice President - Early Development

Who owns Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Rockefeller Financial Services Inc. (0.39%), Russell Investments Group Ltd. (0.28%), Peregrine Capital Management LLC (0.23%), Public Employees Retirement Association of Colorado (0.02%), Aperio Group LLC (0.02%) and Bank of Montreal Can (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Rockefeller Financial Services Inc., Russell Investments Group Ltd., Peregrine Capital Management LLC, Public Employees Retirement Association of Colorado and Winslow Evans & Crocker Inc.. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Hemenway Trust Co LLC, Capstone Asset Management Co., Nisa Investment Advisors LLC, Aperio Group LLC and Bank of Montreal Can. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy Alnylam Pharmaceuticals stock?

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $79.70.


MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  597 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  792
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $81.17 (1.84% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$99.00HighView Rating Details
7/17/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy -> Buy$80.00 -> $90.00LowView Rating Details
7/11/2017Cowen and CompanyReiterated RatingBuy$100.00LowView Rating Details
7/11/2017Credit Suisse GroupSet Price TargetBuy$96.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
7/10/2017Needham & Company LLCReiterated RatingBuy$98.00LowView Rating Details
7/10/2017Chardan CapitalReiterated RatingBuy$110.00 -> $131.00HighView Rating Details
6/26/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
6/22/2017Jefferies Group LLCReiterated RatingBuy -> Buy$102.00LowView Rating Details
6/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$116.00 -> $126.00LowView Rating Details
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform -> Sell$69.70 -> $67.00LowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$44.00 -> $64.00MediumView Rating Details
5/17/2017Leerink SwannReiterated RatingMarket Perform$53.00 -> $67.00HighView Rating Details
4/17/2017BMO Capital MarketsInitiated CoverageOutperform$73.00MediumView Rating Details
3/20/2017FBR & CoReiterated RatingBuyHighView Rating Details
2/3/2017JMP SecuritiesSet Price TargetBuy$69.00N/AView Rating Details
11/3/2016Barclays PLCReiterated RatingHold$50.00N/AView Rating Details
10/6/2016Stifel NicolausLower Price TargetHold$68.00 -> $36.00N/AView Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings History by Quarter for Alnylam Pharmaceuticals (NASDAQ ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($1.21)N/AView Earnings Details
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
2017 EPS Consensus Estimate: ($5.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.30)($1.33)
Q2 20172($1.30)($1.20)($1.25)
Q3 20172($1.25)($1.21)($1.23)
Q4 20172($1.32)($1.19)($1.26)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 89.00%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017SanofiMajor ShareholderBuy297,501$71.87$21,381,396.87View SEC Filing  
5/30/2017Laurie KeatingSVPBuy11,500$65.35$751,525.00View SEC Filing  
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.00View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.00View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.00View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.35View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Source:
DateHeadline
finance.yahoo.com logoAlnylam to Host Fourth Annual “RNAi Roundtable” Webcast Series
finance.yahoo.com - July 27 at 3:21 PM
nasdaq.com logoSomerville Kurt F Buys JM Smucker Co, Analog Devices Inc, Fortive Corp, Sells NXP ... - Nasdaq
www.nasdaq.com - July 26 at 3:53 PM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:14 AM
nasdaq.com logoALNY Crosses Above Average Analyst Target
www.nasdaq.com - July 21 at 5:23 PM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 4:04 PM
americanbankingnews.com logoZacks: Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $22.22 Million
www.americanbankingnews.com - July 15 at 8:19 AM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 14 at 6:44 PM
americanbankingnews.com logo-$1.20 Earnings Per Share Expected for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) This Quarter
www.americanbankingnews.com - July 13 at 2:16 PM
finance.yahoo.com logoAlnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth
finance.yahoo.com - July 12 at 9:19 PM
seekingalpha.com logoAlnylam Pharmaceuticals (ALNY) & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study - Presentation
seekingalpha.com - July 11 at 9:59 PM
seekingalpha.com logoAlnylam Buckles Down On A Belt Of Rare Diseases - Seeking Alpha
seekingalpha.com - July 11 at 4:59 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma
finance.yahoo.com - July 11 at 4:59 PM
finance.yahoo.com logoAlnylam (ALNY) Stock Down Despite Positive Hemophilia Data
finance.yahoo.com - July 11 at 4:59 PM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - July 11 at 4:10 PM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - July 10 at 11:32 PM
seekingalpha.com logoAlnylam And Sanofi Produce Monster Alternative In Hemophilia Market - Seeking Alpha
seekingalpha.com - July 10 at 8:46 PM
americanbankingnews.com logoNeedham & Company LLC Reiterates "Buy" Rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
www.americanbankingnews.com - July 10 at 7:14 PM
lse.co.uk logoSilence Therapeutics Notes Alnylam Starts Phase III Fitusiran Trial
www.lse.co.uk - July 10 at 3:43 PM
finance.yahoo.com logoAlnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors
finance.yahoo.com - July 10 at 3:43 PM
finance.yahoo.com logoAlnylam Commences Phase III Study for Hemophilia Candidate
finance.yahoo.com - July 10 at 3:43 PM
finance.yahoo.com logoCould Alnylam Have An Edge On This Smaller Biotech In Rare Disease?
finance.yahoo.com - July 10 at 3:43 PM
americanbankingnews.com logoAlnylam Pharmaceuticals' (ALNY) Buy Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - July 10 at 3:04 PM
streetinsider.com logoAlnylam Pharma (ALNY), Sanofi (SNY) Initiate Phase 3 Program for Fitusiran for Hemophilia A and B - StreetInsider.com
www.streetinsider.com - July 8 at 5:03 AM
fool.com logoAlnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why - Motley Fool
www.fool.com - July 8 at 5:03 AM
fool.com logoAlnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why
www.fool.com - July 7 at 10:07 AM
finance.yahoo.com logoBiotechs Gained $1.7 Billion Last Week — Can They Keep Going?
finance.yahoo.com - July 5 at 4:26 PM
americanbankingnews.com logoBidaskClub Downgrades Alnylam Pharmaceuticals, Inc. (ALNY) to Buy
www.americanbankingnews.com - June 29 at 10:32 PM
finance.yahoo.com logo[$$] Alnylam Selloff Looks Like an Overreaction
finance.yahoo.com - June 28 at 3:57 PM
americanbankingnews.com logoCredit Suisse Group Raises Alnylam Pharmaceuticals, Inc. (ALNY) Price Target to $96.00
www.americanbankingnews.com - June 27 at 9:14 AM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - June 27 at 8:06 AM
businesswire.com logoAlnylam and Sanofi Genzyme to Present New Clinical Trial Results ... - Business Wire (press release)
www.businesswire.com - June 27 at 4:31 AM
rttnews.com logoAlnylam: Givosiran Shows Positive Clinical Results In Acute Hepatic Porphyrias
www.rttnews.com - June 26 at 11:29 PM
reuters.com logoBRIEF-Alnylam Pharmaceuticals reports results for Givosiran
www.reuters.com - June 26 at 11:29 PM
finance.yahoo.com logoAlnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis (ISTH) Congress
finance.yahoo.com - June 26 at 11:28 PM
streetinsider.com logoAlnylam Pharma (ALNY) Announced New Positive Clinical Results ... - StreetInsider.com
www.streetinsider.com - June 26 at 3:56 PM
seekingalpha.com logoAlnylam priced at perfection - JPMorgan; shares off 5% - Seeking Alpha
seekingalpha.com - June 26 at 3:56 PM
finance.yahoo.com logoAlnylam Reports New Positive Clinical Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
finance.yahoo.com - June 26 at 3:56 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. (ALNY) Increased by Analyst
www.americanbankingnews.com - June 26 at 7:10 AM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives New Coverage from Analysts at Jefferies Group LLC
www.americanbankingnews.com - June 22 at 11:02 AM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - June 21 at 4:22 PM
americanbankingnews.com logo Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $21.26 Million
www.americanbankingnews.com - June 21 at 9:52 AM
reuters.com logoBRIEF-Alnylam CEO, John Maraganore, named BIO chair for 2017-2018 term
www.reuters.com - June 20 at 1:11 AM
finance.yahoo.com logoAlnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term
finance.yahoo.com - June 20 at 1:11 AM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 19 at 6:58 PM
americanbankingnews.com logoZacks: Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) to Post -$1.22 Earnings Per Share
www.americanbankingnews.com - June 19 at 2:06 PM
americanbankingnews.com logoBidaskClub Upgrades Alnylam Pharmaceuticals, Inc. (ALNY) to "Strong-Buy"
www.americanbankingnews.com - June 18 at 1:52 PM
finance.yahoo.com logoWhy is Alnylam's (ALNY) Stock Close to 100% this Year?
finance.yahoo.com - June 15 at 5:06 PM
streetinsider.com logoAlnylam Pharma (ALNY) Reports Expansion of Patent Portfolio with ... - StreetInsider.com
www.streetinsider.com - June 13 at 8:30 PM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 13 at 4:40 PM
americanbankingnews.com logoAlnylam Pharmaceuticals, Inc. (ALNY) Given a $110.00 Price Target at Chardan Capital
www.americanbankingnews.com - June 13 at 2:12 PM

Social

Chart

Alnylam Pharmaceuticals (ALNY) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff